{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T04:11:03Z","timestamp":1795147863117,"version":"4.10.3"},"reference-count":139,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.fjurol.2024.102741","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T04:00:03Z","timestamp":1732248003000},"page":"102741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2024\u20132026: Muscle-invasive bladder cancer (MIBC)"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-146X","authenticated-orcid":false,"given":"Mathieu","family":"Roumigui\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1806-1448","authenticated-orcid":false,"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Bajeot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5526-077X","authenticated-orcid":false,"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-3295","authenticated-orcid":false,"given":"Priscilla","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-2075","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Prad\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriane","family":"Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6_suppl.","key":"10.1016\/j.fjurol.2024.102741_bib0700","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1200\/JCO.2022.40.6_suppl.533","article-title":"Outcomes according to histological variants of urothelial carcinoma after neoadjuvant chemotherapy in the GETUG-AFU V05 VESPER trial","volume":"40","author":"Allory","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102741_bib0705","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2023.01.016","article-title":"Disease-free survival analysis for patients with high-risk muscle-invasive urothelial carcinoma from the randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score","volume":"83","author":"Galsky","year":"2023","journal-title":"Eur Urol"},{"issue":"21","key":"10.1016\/j.fjurol.2024.102741_bib0710","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib0715","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000512053","article-title":"Complete transurethral resection before radical cystectomy may improve oncological outcomes","volume":"106","author":"Graffeille","year":"2022","journal-title":"Urol Int"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102741_bib0720","doi-asserted-by":"crossref","first-page":"787.e9","DOI":"10.1016\/j.urolonc.2021.03.025","article-title":"Survival and oncologic outcomes of complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"39","author":"Pak","year":"2021","journal-title":"Urol Oncol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102741_bib0725","doi-asserted-by":"crossref","first-page":"736.e11","DOI":"10.1016\/j.urolonc.2020.05.032","article-title":"Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?","volume":"38","author":"Ghandour","year":"2020","journal-title":"Urol Oncol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102741_bib0730","doi-asserted-by":"crossref","first-page":"572.e21","DOI":"10.1016\/j.urolonc.2019.04.027","article-title":"The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer","volume":"37","author":"Waingankar","year":"2019","journal-title":"Urol Oncol"},{"issue":"2 Pt 1","key":"10.1016\/j.fjurol.2024.102741_bib0735","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0022-5347(01)69073-6","article-title":"Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder","volume":"167","author":"Nixon","year":"2002","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102741_bib0740","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/bju.13370","article-title":"Urethral recurrence after cystectomy: current preventative measures, diagnosis and management","volume":"117","author":"Chan","year":"2016","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib0745","first-page":"1290","article-title":"The value of cystoscopy, prostate biopsy and frozen-section urethral biopsy prior to orthotopic neobladder substitution","volume":"8","author":"Bulbul","year":"2001","journal-title":"Can J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib0750","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000019550","article-title":"Urethral recurrence of transitional cell carcinoma of the bladder. Predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatocystectomy","volume":"33","author":"Lebret","year":"1998","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib0755","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.juro.2008.03.037","article-title":"Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction","volume":"180","author":"Kassouf","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2024.102741_bib0760","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.urology.2020.07.034","article-title":"Does ureteral stent drainage prior to cystectomy increase the risk of subsequent upper tract urothelial carcinoma and ureteral complications?","volume":"153","author":"Miest","year":"2021","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib0765","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1148\/radiology.173.2.2798874","article-title":"Bladder cancer: staging with CT and MR imaging","volume":"173","author":"Husband","year":"1989","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib0770","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1148\/radiology.193.1.8090898","article-title":"Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging","volume":"193","author":"Kim","year":"1994","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib0775","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1148\/radiol.2313021253","article-title":"Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging","volume":"231","author":"Kim","year":"2004","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102741_bib0780","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2214\/ajr.180.4.1801045","article-title":"Imaging in oncology from the University of Texas M.D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder","volume":"180","author":"Kundra","year":"2003","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.fjurol.2024.102741_bib0785","doi-asserted-by":"crossref","first-page":"281","DOI":"10.12659\/PJR.896752","article-title":"The role of computerized tomography in the assessment of perivesical invasion in bladder cancer","volume":"81","author":"Oz","year":"2016","journal-title":"Pol J Radiol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib0790","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2214\/AJR.08.1318","article-title":"Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract","volume":"192","author":"Vikram","year":"2009","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib0795","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting And Data System)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib0800","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.euo.2020.02.007","article-title":"Diagnostic performance of vesical imaging reporting and data system for the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"3","author":"Woo","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102741_bib0805","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bju.15188","volume":"126","author":"Del Giudice","year":"2020","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib0810","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1464-410X.2007.06766.x","article-title":"Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour","volume":"99","author":"Cowan","year":"2007","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102741_bib0815","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2214\/AJR.07.3472","article-title":"Pulmonary nodules: detection, assessment, and CAD","volume":"191","author":"Girvin","year":"2008","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102741_bib0820","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1159\/000167836","article-title":"Computerized tomography for detecting perivesical infiltration and lymph node metastasis in invasive bladder carcinoma","volume":"81","author":"Baltaci","year":"2008","journal-title":"Urol Int"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib0825","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000440889","article-title":"Evaluation of computed tomography for lymph node staging in bladder cancer prior to radical cystectomy","volume":"96","author":"Horn","year":"2016","journal-title":"Urol Int"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102741_bib0830","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1464-410X.2010.09212.x","article-title":"Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma","volume":"106","author":"Lodde","year":"2010","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib0835","first-page":"938","article-title":"Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings","volume":"47","author":"Picchio","year":"2006","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib0840","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1148\/radiology.180.2.2068292","article-title":"Upper abdominal lymph nodes: criteria for normal size determined with CT","volume":"180","author":"Dorfman","year":"1991","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib0845","doi-asserted-by":"crossref","first-page":"W95","DOI":"10.2214\/AJR.17.18481","article-title":"The diagnostic performance of MRI for detection of lymph node metastasis in bladder and prostate cancer: an updated systematic review and diagnostic meta-analysis","volume":"210","author":"Woo","year":"2018","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib0850","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000488200","article-title":"Diagnostic accuracy of F-18 FDG PET\/CT for preoperative lymph node staging in newly diagnosed bladder cancer patients: a systematic review and meta-analysis","volume":"95","author":"Ha","year":"2018","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib0855","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/JU.0000000000001006","article-title":"Utility of routine preoperative 18F-fluorodeoxyglucose positron emission tomography\/computerized tomography in identifying pathological lymph node metastases at radical cystectomy","volume":"204","author":"Dason","year":"2020","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib0860","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","article-title":"EAU-ESMO consensus statements on the management of advanced and variant bladder cancer\u00a0\u2013\u00a0An international collaborative multistakeholder effort\u2020: under the auspices of the EAU-ESMO Guidelines Committees","volume":"77","author":"Witjes","year":"2020","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102741_bib0865","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.ejrad.2011.07.018","article-title":"Clinical value of FDG PET or PET\/CT in urinary bladder cancer: a systemic review and meta-analysis","volume":"81","author":"Lu","year":"2012","journal-title":"Eur J Radiol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib0870","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib0875","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.fjurol.2024.102741_bib0880","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER Trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib0885","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib0890","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102741_bib0895","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/JU.0000000000003836","article-title":"Impact of divergent differentiation and\/or histological subtype of urothelial carcinoma on patient outcomes in the GETUG-AFU V05 VESPER Trial","volume":"211","author":"Allory","year":"2024","journal-title":"J Urol"},{"issue":"34","key":"10.1016\/j.fjurol.2024.102741_bib0900","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib0905","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0022-5347(05)64046-3","article-title":"The impact of co-morbid disease on cancer control and survival following radical cystectomy","volume":"169","author":"Miller","year":"2003","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102741_bib0910","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","article-title":"Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients","volume":"61","author":"Hautmann","year":"2012","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib0915","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bju.12566","article-title":"Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base","volume":"114","author":"Nielsen","year":"2014","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib0920","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.euo.2019.09.008","article-title":"A Systematic review and meta-analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients","volume":"3","author":"Russell","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib0925","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bju.14211","article-title":"Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy","volume":"122","author":"Mmeje","year":"2018","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102741_bib0930","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2018.09.004","article-title":"Delaying radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer is associated with adverse survival outcomes","volume":"2","author":"Boeri","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib0935","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.juro.2010.02.015","article-title":"Radical cystectomy in octogenarians\u00a0\u2013\u00a0does morbidity outweigh the potential survival benefits?","volume":"183","author":"Donat","year":"2010","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib0940","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.juro.2014.07.090","article-title":"Prostate capsule sparing versus nerve sparing radical cystectomy for bladder cancer: results of a randomized, controlled trial","volume":"193","author":"Jacobs","year":"2015","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib0945","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/bju.13819","article-title":"Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer","volume":"120","author":"Veskim\u00e4e","year":"2017","journal-title":"BJU Int"},{"issue":"10139","key":"10.1016\/j.fjurol.2024.102741_bib0950","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/S0140-6736(18)30996-6","article-title":"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial","volume":"391","author":"Parekh","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib0955","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/JU.0000000000000565","article-title":"Predictors of recurrence, and progression-free and overall survival following open versus robotic radical cystectomy: analysis from the RAZOR Trial with a 3-year follow-up","volume":"203","author":"Venkatramani","year":"2020","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib0960","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bju.14870","article-title":"Robot-assisted vs. open radical cystectomy for bladder cancer in adults","volume":"125","author":"Rai","year":"2020","journal-title":"BJU Int"},{"issue":"21","key":"10.1016\/j.fjurol.2024.102741_bib0965","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1001\/jama.2022.7393","article-title":"Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs. open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomized clinical trial","volume":"327","author":"Catto","year":"2022","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib0970","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.euo.2019.09.008","article-title":"A systematic review and meta-analysis of delay in radical cystectomy and the effect on survival in bladder cancer patients","volume":"3","author":"Russell","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib0975","doi-asserted-by":"crossref","first-page":"354e1","DOI":"10.1016\/j.urolonc.2019.01.028","article-title":"Robotic vs. open cystectomy: How length-of-stay differences relate conditionally to age","volume":"37","author":"Faraj","year":"2019","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib0980","doi-asserted-by":"crossref","first-page":"e2317255","DOI":"10.1001\/jamanetworkopen.2023.17255","article-title":"Cost-effectiveness of robot-assisted radical cystectomy vs. open radical cystectomy for patients with bladder cancer","volume":"6","author":"Dixon","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib0985","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2014.12.009","article-title":"Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel","volume":"67","author":"Wilson","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib0990","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12957-019-1759-5","article-title":"Extended versus non-extended lymphadenectomy during radical cystectomy for patients with bladder cancer: a meta-analysis of the effect on long-term and short-term outcomes","volume":"17","author":"Wang","year":"2019","journal-title":"World J Surg Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib0995","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.eururo.2014.05.031","article-title":"The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review","volume":"66","author":"Bruins","year":"2014","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102741_bib1000","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.eururo.2018.09.047","article-title":"Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial","volume":"75","author":"Gschwend","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib1005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/bju.14850","article-title":"Long-term functional and oncological outcomes of nerve-sparing and prostate capsule-sparing cystectomy: a single-centre experience","volume":"125","author":"Saad","year":"2020","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102741_bib1010","first-page":"805","article-title":"[Guidelines for Clinical Practice of the French College of Obstetricians and Gynecologists 2021: prophylactic procedures associated with gynecologic surgery]","volume":"49","author":"Touboul","year":"2021","journal-title":"Gynecol Obstet Fertil Senol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102741_bib1015","doi-asserted-by":"crossref","first-page":"659.e1","DOI":"10.1016\/j.urolonc.2017.06.053","article-title":"Predictive factors for final pathologic ureteral sections on 700 radical cystectomy specimens: implications for intraoperative frozen section decision-making","volume":"35","author":"Masson-Lecomte","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102741_bib1020","article-title":"Accuracy of frozen section analysis of urethral and ureteral margins during radical cystectomy for bladder cancer: a systematic review and diagnostic meta-analysis","author":"Laukhtina","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102741_bib1025","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/JU.0000000000000034","article-title":"Positive pre-cystectomy biopsies of the prostatic urethra or bladder neck do not necessarily preclude orthotopic bladder substitution","volume":"201","author":"Roth","year":"2019","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib1030","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.urology.2005.09.043","article-title":"Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?","volume":"67","author":"Spiess","year":"2006","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib1035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.purol.2018.12.002","article-title":"[Short version of recommendations for enhanced recovery program (ERP) for cystectomy: technical measures]","volume":"29","author":"Poinas","year":"2019","journal-title":"Prog Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib1040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.juro.2013.08.019","article-title":"A new concept for early recovery after surgery for patients undergoing radical cystectomy for bladder cancer: results of a prospective randomized study","volume":"191","author":"Karl","year":"2014","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102741_bib1045","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.juro.2015.05.083","article-title":"Postoperative pain management after radical cystectomy: comparing traditional versus enhanced recovery protocol pathway","volume":"194","author":"Xu","year":"2015","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102741_bib1050","doi-asserted-by":"crossref","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. Williams BO, editor","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib1055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eururo.2021.09.028","article-title":"Adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials","volume":"81","year":"2022","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.fjurol.2024.102741_bib1060","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102741_bib1065","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102741_bib1070","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ctrv.2018.07.011","article-title":"Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: a systematic-review and framework for adjuvant radiotherapy","volume":"70","author":"Sargos","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.fjurol.2024.102741_bib1075","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2147\/CMAR.S69055","article-title":"Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients","volume":"6","author":"Bayoumi","year":"2014","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib1080","doi-asserted-by":"crossref","first-page":"e174591","DOI":"10.1001\/jamasurg.2017.4591","article-title":"Adjuvant sandwich chemotherapy plus radiotherapy vs. adjuvant chemotherapy alone for locally advanced bladder cancer after radical cystectomy: a randomized phase 2 trial","volume":"153","author":"Zaghloul","year":"2018","journal-title":"JAMA Surg"},{"key":"10.1016\/j.fjurol.2024.102741_bib1085","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2021.06.011","article-title":"Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder","volume":"161","author":"Khalifa","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.fjurol.2024.102741_bib1090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13014-015-0499-0","article-title":"Promising results with image guided intensity modulated radiotherapy for muscle invasive bladder cancer","volume":"10","author":"Whalley","year":"2015","journal-title":"Radiat Oncol Lond Engl"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib1095","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.radonc.2016.09.006","article-title":"Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials","volume":"121","author":"Caffo","year":"2016","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib1100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712\u00a0\u2013\u00a0A randomized phase II trial","volume":"37","author":"Coen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.fjurol.2024.102741_bib1105","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib1110","first-page":"985","article-title":"15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment","volume":"31","author":"Krause","year":"2011","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102741_bib1115","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE\u00a0\u2013\u00a0a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib1120","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital Experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"issue":"33","key":"10.1016\/j.fjurol.2024.102741_bib1125","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.fjurol.2024.102741_bib1130","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity Score Analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib1135","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib1140","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.eururo.2009.12.002","article-title":"Differential complication rates following radical cystectomy in the irradiated and nonirradiated pelvis","volume":"57","author":"Ramani","year":"2010","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib1145","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib1150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"issue":"14","key":"10.1016\/j.fjurol.2024.102741_bib1155","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2002.11.027","article-title":"Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results","volume":"20","author":"R\u00f6del","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib1160","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.fjurol.2024.102741_bib1165","first-page":"1","article-title":"A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer","volume":"31","author":"Portner","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.fjurol.2024.102741_bib1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2024.01.014","article-title":"Benefit of neoadjuvant cisplatin-based chemotherapy for invasive bladder cancer patients treated with radiation-based therapy in a real-world setting: an inverse probability treatment weighted analysis","author":"Kool","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib1175","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"issue":"33","key":"10.1016\/j.fjurol.2024.102741_bib1180","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102741_bib1185","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","article-title":"Long-term outcomes of radical radiation therapy with hypoxia modification with biomarker discovery for stratification: 10-year update of the BCON (Bladder Carbogen Nicotinamide) phase 3 randomized trial (ISRCTN45938399)","volume":"110","author":"Song","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.fjurol.2024.102741_bib1190","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2021.06.011","article-title":"Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder","volume":"161","author":"Khalifa","year":"2021","journal-title":"Radiother Oncol"},{"issue":"27","key":"10.1016\/j.fjurol.2024.102741_bib1195","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.23.00725","article-title":"Bladder-sparing treatment with radical dose radiotherapy is an effective alternative to radical cystectomy in patients with clinically node-positive nonmetastatic bladder cancer","volume":"41","author":"Swinton","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102741_bib1200","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1007\/s00345-023-04506-9","article-title":"Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer","volume":"41","author":"Reignier","year":"2023","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102741_bib1205","doi-asserted-by":"crossref","first-page":"299e7","DOI":"10.1016\/j.urolonc.2020.10.001","article-title":"Refining assessment of response to radiation-based therapy for muscle-invasive bladder cancer: is post-treatment tumor bed biopsy always necessary?","volume":"39","author":"Kool","year":"2021","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib1210","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.juro.2017.08.106","article-title":"Incidence, clinicopathological risk factors, management and outcomes of nonmuscle invasive recurrence after complete response to trimodality therapy for muscle invasive bladder cancer","volume":"199","author":"Sanchez","year":"2018","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib1215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JU.0000000000001696","article-title":"Complications and outcomes of salvage cystectomy after trimodality therapy","volume":"206","author":"Pieretti","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib1220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/JU.0000000000001696","article-title":"Complications and outcomes of salvage cystectomy after trimodality therapy","volume":"206","author":"Pieretti","year":"2021","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib1225","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.21037\/tau.2020.03.04","article-title":"Partial cystectomy for muscle-invasive bladder cancer: a review of the literature","volume":"9","author":"Peak","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib1230","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.euf.2018.12.002","article-title":"Urothelial carcinoma in bladder diverticula: a multicenter analysis of characteristics and clinical outcomes","volume":"6","author":"Voskuilen","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102741_bib1235","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.seminoncol.2012.08.011","article-title":"Urachal adenocarcinoma: a clinician's guide for treatment","volume":"39","author":"Siefker-Radtke","year":"2012","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib1240","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.clgc.2019.09.008","article-title":"Partial cystectomy with pelvic lymph node dissection for patients with nonmetastatic stage pT2-T3 urothelial carcinoma of urinary bladder: temporal trends and survival outcomes","volume":"18","author":"Mistretta","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102741_bib1245","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/bju.13535","article-title":"Robot-assisted partial cystectomy: perioperative outcomes and early oncological efficacy","volume":"119","author":"Golombos","year":"2017","journal-title":"BJU Int"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102741_bib1250","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.urolonc.2019.07.018","article-title":"Impact of surgical technique on surgical margin status following partial cystectomy","volume":"37","author":"Owyong","year":"2019","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102741_bib1255","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1200\/JCO.1998.16.4.1298","article-title":"Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome","volume":"16","author":"Herr","year":"1998","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102741_bib1260","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/cncr.11232","article-title":"Can patient selection for bladder preservation be based on response to chemotherapy?","volume":"97","author":"Sternberg","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib1265","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1590\/S1677-5538.IBJU.2013.06.06","article-title":"The efficacy of hemostatic radiotherapy for bladder cancer-related hematuria in patients unfit for surgery","volume":"39","author":"Lacarri\u00e8re","year":"2013","journal-title":"Int Braz J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib1270","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2021.01.009","article-title":"A tailored radiation therapy strategy for older patients with localized bladder cancer not eligible for curative treatment","volume":"110","author":"Sargos","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.fjurol.2024.102741_bib1275","series-title":"Bladder cancer (Version 2. 2022) [Internet]. NCCN guidelines","year":"2022"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102741_bib1280","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3233\/BLC-170137","article-title":"Chemotherapy versus chemoradiation for node-positive bladder cancer: practice patterns and outcomes from the National Cancer Data Base","volume":"3","author":"Haque","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.fjurol.2024.102741_bib1285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.09.015","article-title":"Pathological downstaging and survival after induction chemotherapy and radical cystectomy for clinically node-positive bladder cancer\u00a0\u2013\u00a0Results of a nationwide population-based study","volume":"69","author":"Hermans","year":"2016","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib1290","doi-asserted-by":"crossref","first-page":"76.e19","DOI":"10.1016\/j.urolonc.2019.09.003","article-title":"Clinically node-positive (cN+) urothelial carcinoma of the bladder treated with chemotherapy and radical cystectomy: clinical outcomes and development of a postoperative risk stratification model","volume":"38","author":"Al-Alao","year":"2020","journal-title":"Urol Oncol"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102741_bib1295","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.fjurol.2024.102741_bib1300","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.fjurol.2024.102741_bib1305","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.fjurol.2024.102741_bib1310","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results From the JAVELIN Bladder 100 Trial After\u00a0\u2265\u00a02 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.fjurol.2024.102741_bib1315","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib1320","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mdr156","article-title":"Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma","volume":"23","author":"Galsky","year":"2012","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102741_bib1325","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/annonc\/mdz214","article-title":"Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a retrospective International Study of Invasive\/Advanced Cancer of the Urothelium (RISC)","volume":"30","author":"Bamias","year":"2019","journal-title":"Ann Oncol"},{"issue":"10236","key":"10.1016\/j.fjurol.2024.102741_bib1330","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102741_bib1335","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102741_bib1340","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102741_bib1345","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102741_bib1350","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib1355","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102741_bib1360","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ejca.2012.01.022","article-title":"Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen","volume":"48","author":"Edeline","year":"2012","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102741_bib1365","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.purol.2015.05.012","article-title":"Surveillance of urothelial carcinomas: review by the Oncology Committee of the French Urology Association","volume":"25","author":"Colin","year":"2015","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib1370","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/MOU.0000000000000752","article-title":"Ureteral and urethral recurrence after radical cystectomy: a systematic review","volume":"30","author":"Carando","year":"2020","journal-title":"Curr Opin Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102741_bib1375","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00330-019-06530-z","article-title":"Imaging protocols for renal multiparametric MRI and MR urography: results of a consensus conference from the French Society of Genitourinary Imaging","volume":"30","author":"Rouvi\u00e8re","year":"2020","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102741_bib1380","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.juro.2013.09.011","article-title":"Long-term renal function outcomes after radical cystectomy","volume":"191","author":"Eisenberg","year":"2014","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102741_bib1385","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.eururo.2011.08.030","article-title":"Risk factors and outcomes of urethral recurrence following radical cystectomy","volume":"60","author":"Boorjian","year":"2011","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102741_bib1390","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.urolonc.2017.11.007","article-title":"Urethral recurrence after radical cystectomy for urothelial carcinoma: a systematic review and meta-analysis","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024001980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024001980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T04:00:57Z","timestamp":1732248057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393024001980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":139,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2950393024001980"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102741","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2024\u20132026: Muscle-invasive bladder cancer (MIBC)","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102741"}}